Opko Health Inc

Latest Results (15.10.2025):

Opko Health Inc. reported its financial results for the second quarter of 2025, demonstrating a consolidated total revenue of $156.8 million, a decrease from $182.2 million in the same period last year. The company experienced a net loss of $148.4 million, primarily due to non-recurring expenses related to a convertible note exchange. Despite the financial challenges, Opko Health achieved significant milestones in its pharmaceutical and diagnostics segments, advanced its clinical programs, and expanded its stock repurchase initiative.

Revenue Performance

In the second quarter of 2025, Opko Health Inc. reported consolidated total revenues of $156.8 million, down from $182.2 million in the second quarter of 2024. The Pharmaceuticals segment maintained steady revenue at $40.7 million compared to $40.5 million a year earlier, while the Diagnostics segment saw a decline to $101.1 million from $129.4 million due to reduced clinical test volumes.

Net Loss and Expenses

The company recorded a net loss of $148.4 million, or $0.19 per share, for the second quarter of 2025, significantly higher than the $10.3 million net loss reported in the same period of 2024. This increase was primarily driven by a $91.7 million non-recurring expense related to the convertible note exchange. Operating losses were $60.0 million compared to $61.7 million in the prior year.

Pharmaceuticals Segment Highlights

Revenue from Pharmaceuticals remained stable at $40.7 million, with growth in certain international markets partially offset by lower sales in Chile. The segment saw an increase in revenue from the BARDA contract and commercial milestones, despite slightly reduced payments for NGENLA. Research and development expenses rose due to expanded collaborations and preparation for new drug applications.

Diagnostics Segment Highlights

Diagnostics revenue decreased to $101.1 million from $129.4 million year-over-year, primarily due to lower clinical test volumes following the sale of certain BioReference assets. However, this was partially offset by higher clinical test reimbursement rates. The segment continues to implement cost-reduction initiatives, resulting in decreased total costs and expenses.

Business Developments

Opko Health advanced several key projects, including Merck's Phase 1 Epstein-Barr virus vaccine trial and ModeX's immuno-oncology portfolio. The company also presented promising preclinical data for OPK-88006 at the American Diabetes Association and ENDO 2025 meetings, and received FDA approval for the supplemental application of the 4KScore® Test without requiring digital rectal examination information.

Stock Repurchase Program

The Board of Directors authorized an additional $100 million for the stock repurchase program, increasing the total capacity to $200 million. As of June 30, 2025, approximately $58.5 million of Opko’s common stock has been repurchased, representing about 14% of the company's outstanding shares.

Cash Position

As of June 30, 2025, Opko Health maintained a strong cash position with $285.4 million in cash, cash equivalents, and restricted cash. During the second quarter, the company completed an exchange agreement to purchase $159.2 million of convertible notes, enhancing its financial stability.